地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18995651644
传真：18372041646
邮箱：sales@amyjet.com
<艾美捷科技代理Helvetica Health Care品牌全系列产品
Helvetica Health Care是一家位于瑞士日内瓦的医疗保健公司，致力于通过创新的产品和技术来管理健康和提高生活质量。作为瑞士生物技术协会的成员，Helvetica Health Care通过了ISO 13485认证，在质量和创新方面坚持最高标准。涵盖各种质量控制和验证面板，适用于不同的分子测试平台和检测。这些产品有多种规格，可用于单一或多种分析物的检测，帮助实验室监控测试性能，确保测试的准确性和可靠性。其质量控制和验证组合可根据产品配置、填充量和分析物浓度进行定制，满足不同平台的需求。
▎Helvetica Health Care产品线
Helvetica Health Care公司的产品涵盖：抗体、生命科学产品、血液分离产品、临床/诊断样本、质控品与标准品、分子生物学产品、细胞因子与生长因子、ELISA试剂盒/Western印迹相关产品、微生物、氧化应激产品、诊断产品以及人血浆制品。
▎Helvetica Health Care部分产品列表
| 货号 | 产品描述 |
| NATFRC-6C | NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) |
| NATCV9-6C | NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5mL) |
| NATRPC2.1-BIO | NATtrol Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL) |
| NATRVP2.1-BIO | NATtrol Respiratory Verification Panel 2.1 (24 x 0.6mL) (EA) |
| NATRVP2.1-BIO Plus | NATtrol Respiratory Verification Panel 2 Plus (+NATCOV(MR)-BIO) (24x 0.6 ml + 1x 0.6 ml) |
| NATRVP2-QIA | NATtrol Respiratory Verification Panel 2 (21 x 0.25mL) (EA) |
| NATSARS(COV2)-VP | NATtrol SARS-CoV-2 Variant Panel (4 x 0.5mL) |
| NATSARS(COV2)-ERC | SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL) |
| NATSARS(COV2)-ERC1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Positive Control (6x 1.0 ml) |
| NATSARS(COV2)-NEG | SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL) |
| NATSARS(COV2)-NEG1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Negative Control (6x 1.0 ml) |
| NATSARS(COV2)-ST | SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
| NATSARS(COV2-SA)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock (1mL) |
| NATSARS(COV2-UK)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.1.7 Stock (1mL) |
| 0810229-0.5mg | Coronavirus 229E Lysate (0.5 mg) |
| 0810587 | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (1 mg) |
| 0810587-0.5mg | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (0.5 mg) |
| 0810587CFHI-0.5mL | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (0.5 mL) |
| 0810587CFHI | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (1.0 mL) |
| 0810587UV | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810589CFHI | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810589UV | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (UV Inactivated) (1 mL) |
| 0810590CFHI | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810590UV | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810617UV | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) Culture Fluid (UV)) |
| 0810618UV | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) Culture Fluid (UV) |
| 0810619UV | SARS-CoV-2 Iso1 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810620UV | SARS-CoV-2 Iso2 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810621UV | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) CF (UV Inactivated) |
| 0810622UV | SARS-CoV-2 Lineage B.1.595_2020 (NY-Wadsworth-33126-01/2020) CF (UV Inactivated) |
| 0810612CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:USA/CA_CDC_5574/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810612UV | SARS-CoV-2 Lineage B.1.1.7; Alpha Variant (USA/CA_CDC_5574/2020) CF (UV Inactivated) (1 mL) |
| 0810613CFHI | SARS-CoV-2 Variant B.1.351(Isolate:South_Africa/KRISP-K005325/2020) CF (Heat Inactivated) (1 mL) |
| 0810613UV | SARS-CoV-2 Lineage B.1.351; Beta (South_Africa/KRISP-K005325/2020) CF (UV Inactivated) (1 mL) |
| 0810614CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:England/204820464/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810614UV | SARS-CoV-2 Lineage B.1.1.7 Alpha Variant (England/204820464/2020) CF (UV Inactivated) (1 mL) |
| 0810616CFHI | SARS-CoV-2 Lineage P1; Gamma Variant (Japan/TY7-503/2021) CF (Heat Inactivated) (1 mL) |
| 0810616UV | SARS-CoV-2 Lineage P1; Gamma Variant (Isolate: Japan/TY7-503/2021) CF (UV Inactivated) (1 mL) |
| 0810617CFHI | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) – CFHI (1.0 ml) |
| 0810618CFHI | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) – CFHI (1.0 ml) |
| 0810619CFHI | SARS-CoV-2 Lso1 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810620CFHI | SARS-CoV-2 Lso2 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810621CFHI | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) – CFHI (1.0 ml) |
| 0810622CFHI | SARS-CoV-2 Lineage E3.1.595J2020 (NYWadsworth-33126-01/2020) – CFHI (1.0 ml) |
| 0810623UV | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (UV Inactivated) |
| 0810623CFHI | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (Heat Inactivated) |
| 0810624UV | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (UV Inactivated) |
| 0810624CFHI | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (Heat Inactivated) |
| 0820010CFHI | VeroE6 Culture Fluid (Heat Inactivated) (1 mL) |
| 0801043 | Goat Anti-SARS-CoV-2 Polyclonal Serum (0.5 ml) |
| 0831042 | SARS-CoV-2 (recombinant) Stock (1 x 1.0 mL) |
| 0831043 | SARS-CoV-2 (E/ORF1ab recombinant) Stock (1 x1.0mL) |
| NATSARS-ST | Coronavirus SARS Stock (Qualitative) (1 mL) |
| NATCOV(229E)-ST | Coronavirus 229E Stock (Qualitative) (1 mL) |
| 0810229CFHI | Coronavirus (Strain: 229E) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810229 | Coronavirus Strain: 229E Lysate |
| 0810229UV | Coronavirus (Strain: 229E) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(NL63)-ST | Coronavirus NL63 Stock (Qualitative) (1 mL) |
| 0810228CFHI | Coronavirus (Strain: NL63) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810228 | Coronavirus Strain: NL63 Lysate |
| 0810228UV | Coronavirus (Strain: NL63) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(OC43)-ST | Coronavirus OC43 Stock (Qualitative) (1 mL) |
| 0810024CFHI | Coronavirus (Strain: OC43) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810024 | Coronavirus Strain: OC43 Lysate |
| NATMERS-ST | MERS-CoV Stock (Qualitative) (1 mL) |
| NATMR-BIO | NATtrol MERS Recombinant Pack (2x 0.2 ml +0.5 ml) |
| NATCOV(MR)-BIO | NATtrol MERS-S. Cerevisiae (0.6 ml) |
| 0810575 | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(1mg) |
| 0810575-0.5mg | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(0.5mg) |
| CV033122 | COVID-19 Cross Over Panel (40x 1.0 ml) |
invivoCrown IV0103替换BioXCell BE0075-1
invivoCrown IV0102替换BioXCell BE0003-1
invivoCrown IV0118替换BioXCell BE0055
<艾美捷科技代理Carbon Solutions品牌全系列产品
Carbon Solutions，Inc.（CSI）是一个在碳纳米管技术领域具有显著影响力的品牌，CSI成立于1998年，位于加利福尼亚州里弗赛德。公司自成立之初就明确了其核心目标，即批量生产单壁碳纳米管（SWNT）。CSI因其生产的高质量碳纳米管材料而享有盛誉，已成为领先的纳米技术公司之一。公司能够生产几乎适用于任何应用的碳纳米管，这得益于其对单壁纳米管进行化学处理的能力，从而引入必要的化学官能团，以与常见的工业过程兼容。此外，CSI还是纯度评估技术开发领域的领导者，并制定了碳纳米管工业销售的质量控制和质量保证标准。
▍Carbon Solutions产品列表
| 品名 | Carbonaceous_Purity | METAL CONTENT | 规格 | 描述 |
| AP-SWNT | 60 - 70% | < 30 wt% from TGA in air | 1 gram | As prepared single-wall carbon nanotubes |
| P2-SWNT | > 90% | 4 - 8 wt. % from TGA in air | 0.5 grams | Purified, low functionality single-wall carbon nanotubes |
| P3-SWNT | > 90% | 5 - 7 wt. % from TGA in air | 0.5 grams | Purified, high functionality single-wall carbon nanotubes |
| P33-SWNT | > 90% | 4 - 6 wt. % from TGA in air | 0.1 grams | Ultra high purity SWNTs with 1– 3 atomic % carboxylic acid groups, which can be derivatized with a variety of functional groups. |
| P5-SWNT | > 90% (65% ± 15% SWNT loading) | 4 - 6 wt. % from TGA in air | 0.1 grams | Organic soluble, single-wall carbon nanotubes functionalized with ODA |
| P7-SWNT | > 90% (80% ± 10% SWNT loading) | 4 - 6 wt. % from TGA in air | 0.1 grams | Water soluble (single-wall carbon nanotubes functionalized with PEG) |
| P8-SWNT | > 90% (35% ± 10% SWNT loading) | 1 - 3 wt. % from TGA in air | 0.1 grams | Water soluble (functionalized with PABS) |
| P9-SWNT | > 90% | 5 - 8 wt. % from TGA in air | 0.1 grams | Amide functionalized SWNTs |
| i-SWNT | > 45% | < 30 wt. % from TGA in air | 1 gram | Industrial grade electric arc SWNTs synthesized using Ni/Y catalyst |
| ip-SWNT | > 90% | > 5 wt. % from TGA in air | 1 gram | Industrial grade SWNTs purified by air oxidation and subsequently treated to remove the catalyst. Low functionality and low chemical doping |
| ipcx-SWNT | > 90% | > 5 wt. % from TGA in air | 1 gram | Industrial grade purified SWNTs with carboxylic acid groups |
| GO | N/A | N/A | 0.5 grams | Graphene oxide |
| rGO | N/A | N/A | 0.5 grams | Synthesized by reduction of GO using sodium borohydride. |
| NrGO | - | < 1 wt. % from TGA in air | 0.5 grams | Nitrogen-doped reduced graphene oxide |
invivoCrown IV0104替换BioXCell BE0061
invivoCrown IV0117替换BioXCell BE0223
invivoCrown IV0115替换BioXCell BE0060
ChromaDex公司成立于1999年，主要产品天然提取物标准物质，同时还提供天然提取物检测、评价、开发服务。ChromaDex始终紧跟政府、市场及客户要求，持续推出新产品，以满足不断发展的检测方法。
ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. Our flagship ingredient, NIAGEN®, is sold directly to consumers as TRU NIAGEN® and is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®.
ChromaDex的主要产品包括：
Phytochemical Reference Standards
Botanical Reference Materials
Natural Product Libraries
NIAGEN
pTeroPure
PURENERGY
IMMULINA
AnthOrigin
" data-original="http://eurogentec.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="ChromaDex"> ChromaDex
invivoCrown IV0113替换BioXCell BE0075
地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：15172469628
传真：13212737804
邮箱：sales@amyjet.com
0.2015
